These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email corporaterelations@oss-oncology.org for assistance.
This strategy report outlines five actionable priorities to improve bladder cancer care across health systems. It also focuses on patient education, care coordination, referral pathways, provider knowledge, and program measurement. The report addresses the challenges posed by high recurrence rates, complex patient populations, and evolving therapies, highlighting the need for standardized, guideline-concordant care. Published - April 2026
The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer. To learn more visit, https://www.bms.com/healthcare-providers/time-back-campaign-honoring-oncologists-in-cancer-care.html
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
ASCENT-04 published in New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2508959
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
ASCENT-03 published in New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2511734
Pfizer and the American Cancer Society are teaming up through Change the Odds to help break barriers in cancer care disparities with a focus on: Cancer Screening, Patient Resources & support, and Clinical Trials. Learn more below.
This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.
Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions. View the full press release.
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. View the full press release.
Posted on 01/15/2026
View the full publication:
View the Plain Language Summary of the publication
© Johnson & Johnson and its affiliates 2025. 12/25 CP-557697v1
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit or download the resource below to learn more.
Posted on 11/12/2025
The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3
Posted on 11/12/2025
In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.
Posted on 11/6/2025
To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.
Posted on 10/29/2025
MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit for more information.
Posted on 10/29/2025
Live: Call 1-877-744-5675 (Monday–Friday 8 AM–8 PM ET)
Online: Visit
Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.
Pfizer Oncology Together can help healthcare providers by:
Pfizer Oncology Together can help patients by:
Please visit http://PfizerOncologyTogether.com for more details, or contact your local FRM or AP&R Director to learn more.
© 2024 Pfizer Inc. All rights reserved. PP-UNP-USA-4653 September 2024
Posted on 1/16/2025
Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
Posted on 12/28/2024
Posted on 12/02/2024
HCP’s: Use these handouts to help patients understand their Medicare plan:
Posted on 11/20/2024
FDA-Approved Therapy and ICD-10-CM Codes for Desmoid Tumors. Desmoid tumors are rare, locally aggressive soft tissue tumors that are characterized by high rates of initial misdiagnosis.
Posted on 11/13/2024
Changes to Medicare Part D in 2025 will Cap Out-Of-Pocket (OOP) Costs for Patients. Please feel free to review & share this important resource.
Posted on 11/09/2024
Johnson and Johnson’s eighth U.S. Pricing Transparency Report provides key data, analysis and insights that will help advance solutions to create a more sustainable, equitable and innovative healthcare system.
Posted on 11/09/2024
Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.
Posted on 11.11.2024
Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).
